WCCT Global, a global CRO supporting phase I-IV bio-pharmaceutical and device development, announced the success of their specialized recruitment methods for ethnobridging studies.

The company has over 10 years of experience in Asian bridging studies. Its geographic location in Southern California has played a major role in enabling it to recruit qualified participants for Asian Bridging Studies. Their volunteer database includes potential volunteers of Japanese, Chinese, Taiwanese, Asian Indian, Korean and Philippine decent and has grown to be quite extensive and very valuable asset.

WCCT Global was recently chosen to recruit and conduct a very difficult Japanese special population study with very stringent inclusion and exclusion criteria. By utilizing its database in combination with their proprietary, multi-media tools were able to successfully enroll and execute the study ahead of schedule for the sponsor.

WCCT Global has carried out over 60 ethnobridging clinical trials and recruited over 1,200 Asian volunteers since 1993. The recruitment methods that WCCT Global has developed have become such a robust tool for special population studies that sponsors around the world reach out to WCCT Global to help recruit and execute a diverse panel of clinical studies.

The company has released a five-part video series on "The Role of Ethnic Bridging in Enhancing Asset Value and Accelerating Global Drug Development." This video series is to inform sponsors on the importance of developing drugs for the global market.

“We wanted to share some of the knowledge we have gained in this field over the years in order to help sponsors accelerate patient access to new medical treatments, globally,” said Mel Affrime, senior vice president, R&D, WCCT Global.